Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Canadian Cancer Trials Group SC.26 - Emotion and Symptom-Focused Engagement (EASE): A Multi-Site Randomized Controlled Trial of an Intervention for Individuals with Acute Leukemia

Troy Climans, Camilla Zimmermann, Annette E. Hay, Harriet Richardson, Pierre Villeneuve, Lee Mozessohn, Andre C. Schuh, Janique Dyba, Breffni Hannon, David Lee, Rena Buckstein, Argin Malakian, Kyle Fitzgibbon, Joel Lefebvre, Wei Tu, Gary Rodin

Blood (2023) 142 (Supplement 1): 1494.

https://doi.org/10.1182/blood-2023-174378

Published: 2023

Journal Articles

Development and Validation of the Early-Stage Hodgkin Lymphoma (HL) International Prognostication Index (E-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium

Andrew M Evens, Angie Mae Rodday, Matthew J. Maurer, Ranjana H. Advani, Marc Andre, Andrea Gallamini, Annette E. Hay, David Hodgson, Richard T. Hoppe, Martin Hutchings, Peter Johnson, Brian K. Link, Stephen Opat, John M. Raemaekers, Jenica Upshaw, Qingyan Xiang, Nicholas Counsell, Susan K Parsons, John Radford

Blood (2023) 142 (Supplement 1): 3058.

https://doi.org/10.1182/blood-2023-173320

Published: 2023

Journal Articles

Primary Care Management Pathways to Reduce Wait Times in Hematology: Monoclonal Gammopathy of Undetermined Significance

Pallavi Ganguli, Janique Dyba, Annette E. Hay, Liying Zhang, Samuel A Silver, Yun Huang, Kevin Loughlin, Elizabeth Eisenhauer, Bethany Elaine Monteith

Blood (2023) 142 (Supplement 1): 908.

https://doi.org/10.1182/blood-2023-179080

Published: 2023

Journal Articles

Canadian Cancer Trials Group (CCTG) LY.17: A Randomized Phase II Study Evaluating Novel Salvage Therapy Pre-Autologous Stem Cell Transplant (ASCT) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR-DLBCL) - Outcome of Rituximab-Dose-Intensive Cyclophosphamide, Etoposide, Cisplatin (R-DICEP) Versus R-GDP

Douglas A. Stewart, Lois E. Shepherd, Jill J. Dudebout, Jean-François Larouche, Neil Chua, Tara Baetz, Michael Crump, Mona Shafey, Nizar Abdel-Samad, Sue Robinson, Isabelle Fleury, Deborah Marcellus, Pamela Skrabek, Jesse Kelly, Annette E. Hay, Bingshu Chen, John Kuruvilla

Blood (2022) 140 (Supplement 1): 3734–3736.

https://doi.org/10.1182/blood-2022-163706

Published: 2022

Journal Articles

Recurrent Copy Number Alterations Contribute to a Unique Genetic Landscape in Relapsed-Refractory DLBCL

Blood (2022) 140 (Supplement 1): 9259–9260.

https://doi.org/10.1182/blood-2022-169623

Published: 2022

Journal Articles

Evaluation of Infection in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Systematic Review

Anna R. Blankstein, Neelan Sriranjan, Nora Choi, Kristjan Paulson, David Sanford, Lee Mozessohn, Donald S. Houston, Emily Rimmer, Sylvain Lother, Asher Mendelson, Allan Garland, Rena Buckstein, Annette E. Hay, Ryan Zarychanski, Brett L. Houston

Blood (2022) 140 (Supplement 1): 6092–6093.

https://doi.org/10.1182/blood-2022-170961

Published: 2022

Journal Articles

Evaluation of Bleeding and Thrombocytopenia in Older Adults with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Systematic Review and Meta-Analysis

Neelan Sriranjan, Anna R. Blankstein, Nora Choi, Kristjan Paulson, David Sanford, Lee Mozessohn, Donald S. Houston, Emily Rimmer, Sylvain Lother, Asher Mendelson, Allan Garland, Rena Buckstein, Annette E. Hay, Ryan Zarychanski, Brett L. Houston

Blood (2022) 140 (Supplement 1): 11632–11633.

https://doi.org/10.1182/blood-2022-171047

Published: 2022

Journal Articles

Supportive Care Strategies in Myelodysplastic Syndromes and Acute Myeloid Leukemia in Older Adults: A National Survey of Canadian Hematologists

Anna R. Blankstein, Nora Choi, Lee Mozessohn, David Sanford, Kristjan Paulson, Emily Rimmer, Donald S. Houston, Sylvain Lother, Asher Mendelson, Allan Garland, Ryan Zarychanski, Annette E. Hay, Rena Buckstein, Brett L. Houston

Blood (2022) 140 (Supplement 1): 11656–11657.

https://doi.org/10.1182/blood-2022-164450

Published: 2022

Journal Articles

Evaluation of Infection in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A Systematic Review

Jiayu Yang, Nora Choi, Lee Mozessohn, David Sanford, Kristjan Paulson, Donald S. Houston, Emily Rimmer, Sylvain Lother, Asher Mendelson, Allan Garland, Rena Buckstein, Annette E. Hay, Ryan Zarychanski, Brett L. Houston

Blood (2022) 140 (Supplement 1): 12317–12318.

https://doi.org/10.1182/blood-2022-170652

Published: 2022

Journal Articles

Evaluation of Bleeding and Thrombocytopenia in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A Systematic Review

Jiayu Yang, Nora Choi, Kristjan Paulson, David Sanford, Lee Mozessohn, Donald S. Houston, Emily Rimmer, Sylvain Lother, Asher Mendelson, Allan Garland, Rena Buckstein, Annette E. Hay, Ryan Zarychanski, Brett L. Houston

Blood (2022) 140 (Supplement 1): 12315–12316.

https://doi.org/10.1182/blood-2022-170553

Published: 2022

Journal Articles

Development and Testing of a Lymphoma Clinical Trials Specific Frailty Index: A Secondary Analysis of the LY.12 Clinical Trial

Abi Vijenthira, Xinzhi Li, Michael Crump, Annette E. Hay, Lois E. Shepherd, Ralph Meyer, Marina S. Djurfeldt, Bingshu E. Chen, Anca Prica

Blood (2021) 138 (Supplement 1): 4076.

https://doi.org/10.1182/blood-2021-153037

Published: 2021

Journal Articles

Risk Factors for the Development of Skin Cancers in Patients with Chronic Lymphocytic Leukemia: A Retrospective Cohort Study

Ivan Landego, MD, Shirley Li, Chao Xue, Vincent Poon, Robert C. Clayden, MSc, MD, Kevin Ren, Yuka Asai, Annette E. Hay

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-138961

Published: 2020

Journal Articles

A Prospective Economic Analysis of Canadian Cancer Trials Group Clc.2/Alliance A041202: A Randomized Phase III Comparison of Bendamustine-Rituximab Versus Ibrutinib-Based Regimens in Untreated Older Patients with Chronic Lymphocytic Leukemia

Blood (2020) 136 (Supplement 1): 27–30.

https://doi.org/10.1182/blood-2020-136692

Published: 2020

Journal Articles

Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial

Annette E. Hay, Sarit Assouline, MD, Roland B. Walter, MD PhD MS, Richard F. Little, MD MPH, Anna Moseley, M.S., Sperling M Gail, MPH, CHES, Annie Im, MD, James M. Foran, MD, Jerald P. Radich, MD, Min Fang, MD PhD, Megan Othus, PhD, Harry P. Erba, MD PhD, Laura C. Michaelis, MD

Blood (2019) 134 (Supplement_1): 3905.

https://doi.org/10.1182/blood-2019-124320

Published: 2019

Journal Articles

Overall and Progression Free Survival from the Mcrn-003/Myx.1 Trial: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma

Christopher P Venner, MD, Richard Leblanc, MDFRCPC, Irwindeep Sandhu, MDFRCPC, Darrell J White, MD, Andrew Belch, MD, Donna E Reece, MD, Christine I Chen, MD, Sean Dolan, MD, Marc Lalancette, MD FRCP, Martha L Louzada, MDMSc, Andrea Kew, MDFRCP(C), Arleigh McCurdy, MD, Tony Reiman, MD, Max Sherry, Gail T. McDonald, Bethany Elaine Monteith, MD, Engin Gul, BS, MBA, Bingshu E. Chen, Annette E. Hay

Blood (2019) 134 (Supplement_1): 1871.

https://doi.org/10.1182/blood-2019-122637

Published: 2019

Journal Articles

Diagnosing Absolute Iron-Deficiency Anemia in Patients on Hemodialysis in a Tertiary Care Centre: A Retrospective Chart Review

Robert C. Clayden, MSc, MD, Wilma Hopman, MSc, Frances Macleod, RN, David Good, MD FRCPC, Jocelyn Garland, MD FRCPC, Lawrence Hookey, MD FRCPC, Annette E. Hay

Blood (2019) 134 (Supplement_1): 4814.

https://doi.org/10.1182/blood-2019-129197

Published: 2019

Journal Articles

Event-Free Survival As a Surrogate for Overall Survival in Relapsed DLBCL after Autologous Transplant: A Subgroup Analysis of LY.12 and Coral

Sarit Assouline, MD, Shen Li, MD, Christian Gisselbrecht, MD, Patrick Fogarty, Annette E. Hay, Eric Van Den Neste, MD, Lois E. Shepherd, Norbert Schmitz, MD, Tara Baetz, Armand Keating, MD, Sue Robinson, MD, Matthew D. Seftel, FRCP,FRCPC,MPH,MD, Caterina Stelitano, Marina S. Djurfeldt, Ralph Meyer, Bingshu E. Chen, Michael Crump, MD FRCPC

Blood (2019) 134 (Supplement_1): 768.

https://doi.org/10.1182/blood-2019-124879

Published: 2019

Journal Articles

Prognostic Significance of Neutrophil to Lymphocyte Ratio (NLR) in Relapsed/Refractory Aggressive Lymphoma Salvage Chemotherapy — Analysis of Canadian Cancer Trials Group (CCTG) ly.10 Trial

Mina Dehghani Mohammadabadi, MD, Annette E Hay, Lois E. Shepherd, Michael Crump, MD, Bingshu E. Chen, Tara Baetz, MD

Blood (2018) 132 (Supplement 1): 2980.

https://doi.org/10.1182/blood-2018-99-116316

Published: 2018

Journal Articles

MCRN ¯ 003/MYX · 1: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma after 1-3 Prior Therapies

Christopher P. Venner, MD FRCPC, Richard Leblanc, MDFRCPC, Irwindeep Sandhu, MDFRCPC, Darrell J. White, MD, Andrew R Belch, MD, Donna E Reece, MD, Christine I Chen, MD, Sean Dolan, MD, Andrea Kew, MDFRCP(C), Marc Lalancette, MD FRCP, Martha L Louzada, MD, Arleigh McCurdy, MD BSc, Gail T. McDonald, Tony Reiman, MD, Laura Rodriguez, Lois E. Shepherd, Engin Gul, BSc, Bingshu E. Chen, Annette E Hay

Blood (2018) 132 (Supplement 1): 1984.

https://doi.org/10.1182/blood-2018-99-117824

Published: 2018

Journal Articles

Potential Utility of Event-Free Survival (EFS) As Surrogate Endpoint for Overall Survival (OS) in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) after Autologous Stem Cell Transplantation (ASCT): A Subgroup Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Randomized Phase III Trial

Shen Li, MD, Annette E Hay, Michael Crump, MD, Peter Anglin, MD FRCPC, MBA, Tara Baetz, Ralph Meyer, MDFRCPC, Armand Keating, MD, Sue Robinson, MD, Matthew Seftel, MRCP, MD MPH, FRCPC, Caterina Stelitano, Marina S Djurfeldt, MSc, Lois E. Shepherd, Bingshu E. Chen, Sarit Assouline, MD

Blood (2017) 130 (Supplement 1): 2015.

https://doi.org/10.1182/blood.V130.Suppl_1.2015.2015

Published: 2017

NARROW

Canadian Cancer Trials Group SC.26 - Emotion and Symptom-Focused Engagement (EASE): A Multi-Site Randomized Controlled Trial of an Intervention for Individuals with Acute Leukemia

Development and Validation of the Early-Stage Hodgkin Lymphoma (HL) International Prognostication Index (E-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium

Primary Care Management Pathways to Reduce Wait Times in Hematology: Monoclonal Gammopathy of Undetermined Significance

Recurrent Copy Number Alterations Contribute to a Unique Genetic Landscape in Relapsed-Refractory DLBCL

Evaluation of Infection in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Systematic Review

Evaluation of Bleeding and Thrombocytopenia in Older Adults with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Systematic Review and Meta-Analysis

Supportive Care Strategies in Myelodysplastic Syndromes and Acute Myeloid Leukemia in Older Adults: A National Survey of Canadian Hematologists

Evaluation of Infection in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A Systematic Review

Evaluation of Bleeding and Thrombocytopenia in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A Systematic Review

Development and Testing of a Lymphoma Clinical Trials Specific Frailty Index: A Secondary Analysis of the LY.12 Clinical Trial

Risk Factors for the Development of Skin Cancers in Patients with Chronic Lymphocytic Leukemia: A Retrospective Cohort Study

A Prospective Economic Analysis of Canadian Cancer Trials Group Clc.2/Alliance A041202: A Randomized Phase III Comparison of Bendamustine-Rituximab Versus Ibrutinib-Based Regimens in Untreated Older Patients with Chronic Lymphocytic Leukemia

Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial

Overall and Progression Free Survival from the Mcrn-003/Myx.1 Trial: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma

Diagnosing Absolute Iron-Deficiency Anemia in Patients on Hemodialysis in a Tertiary Care Centre: A Retrospective Chart Review

Event-Free Survival As a Surrogate for Overall Survival in Relapsed DLBCL after Autologous Transplant: A Subgroup Analysis of LY.12 and Coral

Prognostic Significance of Neutrophil to Lymphocyte Ratio (NLR) in Relapsed/Refractory Aggressive Lymphoma Salvage Chemotherapy — Analysis of Canadian Cancer Trials Group (CCTG) ly.10 Trial

MCRN ¯ 003/MYX · 1: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma after 1-3 Prior Therapies

Potential Utility of Event-Free Survival (EFS) As Surrogate Endpoint for Overall Survival (OS) in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) after Autologous Stem Cell Transplantation (ASCT): A Subgroup Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Randomized Phase III Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only